Nucala received USFDA approval to treat chronic rhinosinusitis with nasal polyps
GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) have approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5),... Read More
Stada acquired 15 OTC brands of GSK
Stada Arzneimittel AG has acquired 15 consumer healthcare products, including those specializing in vitamins, cold treatments, and sore throat medication, from GlaxoSmithKline... Read More
GSK to disinvest Rabipur and Encepur – vaccine for USD 1.1 billion
Posted on22 Oct 2019
Comments0
GlaxoSmithKline (GSK) will sell two travel vaccines to Bavarian Nordic for up to 955 million euros ($1.1 billion), the British firm said... Read More
GSK to acquire Celiac-Focused Sitari Pharmaceuticals
GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for celiac disease. Sitari, a preclinical-stage biotech, is... Read More
GSK grants exclusive technology license for Ebola vaccines to Sabin Vaccine Institute
GSK and the Sabin Vaccine Institute (Sabin), a non-profit organization, announced exclusive agreements for Sabin to advance the development of the prophylactic... Read More
GSK’s Shingrix received chinese approval for shingles vaccine
Posted on24 May 2019
Comments0
GaxoSmithKline (GSK) has secured approval from China’s National Medical Products Administration (NMPA) for Shingrix vaccine to prevent shingles (herpes zoster) in adults... Read More
GSK’s disinvestment of Chiron Behring to Bharat Biotech
Posted on16 Feb 2019
Tagsacquisition in pharma, Bharat Biotech, Chiron Behring Vaccines, disinvestment in pharma business, GSK, Hoechst AG
Comments0
Bharat Biotech’s recent plans to acquire Chiron Behring Vaccine Private Limited from GlaxoSmithKline Asia, is expected to boost the company’s rabies vaccine... Read More
Pfizer and GlaxoSmithKline to merge consumer healthcare units
Pfizer Inc. and GlaxoSmithKline plc have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.... Read More
Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan
Daiichi Sankyo Company, Limited announced that Daiichi Sankyo and GlaxoSmithKline K.K have agreed to dissolve their joint venture company, Japan Vaccine Co,... Read More
Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK’s Breo Ellipta generics
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close... Read More